Abstract: Mantle cell lymphoma is a clinically and biologically heterogeneous disease that necessitates individualized frontline treatment to balance efficacy and tolerability. Currently, intensified cytarabine⁃containing immunochemotherapy followed by consolidation with autologous hematopoietic stem cell transplantation remains a standard approach for achieving durable remission in transplant⁃eligible patients. In patients who are ineligible for transplantation, bendamustine combined with rituximab has emerged as a commonly used frontline regimen. In recent years, novel agents including Bruton tyrosine kinase inhibitors, BCL⁃2 inhibitors, and immunomodulatory agents have increasingly been integrated with existing standard strategies and shown promising therapeutic potential. This article systematically reviews recent advances in optimizing frontline treatment strategies for newly diagnosed patients with MCL and discusses current challenges and future directions.

Key words: Mantle cell lymphoma, Frontline therapy, Bruton tyrosine kinase inhibitors, Autologous stem cell transplantation, Minimal residual disease